Substance / Medication

Yohimbine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

78 trials linked to this intervention

78
Total Trials
2
Recruiting
14
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effects of Acute Yohimbine Hydrochloride Supplementation on Repeated Supramaximal Sprint Performance.
Barnes Megan E, Cowan Camryn R, Boag Lauren E et al. · Int J Environ Res Public Health · 2022
PMID: 35162339RCTFull text (PMC)
Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial.
Meyerbroeker Katharina, Powers Mark B, van Stegeren Anda et al. · Psychother Psychosom · 2012
PMID: 22116378RCT
Molecular structure, vibrational spectra and HOMO, LUMO analysis of yohimbine hydrochloride by density functional theory and ab initio Hartree-Fock calculations.
Joshi Bhawani Datt, Srivastava Anubha, Tandon Poonam et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2011
PMID: 21856216Other
Yohimbine hydrochloride inhibits skin melanin synthesis by regulating wnt/β-catenin and p38/MAPK signal pathways.
Fu Ting, Qin Xiaofeng, Ma Yining et al. · J Dermatol Sci · 2022
PMID: 35840473Preclinical
Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2.
Zhao Yani, Zhang Yan, Li Yao et al. · Eur J Pharmacol · 2021
PMID: 34265299Preclinical
Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction.
Lebret Thierry, Hervé Jean-Marie, Gorny Philippe et al. · Eur Urol · 2002
PMID: 12074777Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Yohimbine hydrochloride (substance)
SNOMED CT
96264005
UMLS CUI
C0521933

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
78
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.